Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as described herein: Frther provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.

Abstract: A biflavone compound against an I-type herpes simplex virus, and a preparation method therefor and the use thereof. The bioflavone compound is a compound of formula I, or a crystal form thereof, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof, or a prodrug thereof. The biflavone compound has a good inhibitory effect on the I-type herpes simplex virus, has a significant effect on the replication and direct inactivation of the virus, and is dose dependent. The compound is also effective in preventing and/or treating viral keratitis caused by the I-type herpes simplex virus. The compound has good water solubility and low toxicity. It can be prepared into an external preparation for resisting the I-type herpes simplex virus, such as eye drops and eye ointment, and external ointments, creams, gel agents, film agents, film-coating agents, etc.

Abstract: A pyrimidine or pyridine derivative having a structure represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use thereof as an EGFR inhibitor, and a use thereof in the preparation of a drug for treating and/or preventing cancer, tumors, or metastatic diseases associated at least in part with EGFR exon 20 insertions, deletions, or other mutations, especially a use thereof in the preparation of a drug for treating and/or preventing hyperproliferative diseases and the induction of cell death disorders.

Abstract: Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.

Abstract: This application provides a cooling system, including a heat exchanger, a cooling supplement component, a bypass vent valve, and a controller. The heat exchanger includes an air intake vent A and an air exhaust vent B that are used for outdoor fresh air entry and discharge, and an air intake vent C and an air exhaust vent D that are used for indoor return air entry and discharge. The cooling supplement component includes a condenser and an evaporator, the condenser is connected to the air exhaust vent B by using an exhaust air pipe, and the evaporator is connected to the air exhaust vent D. The bypass vent valve is disposed on the exhaust air pipe, and the bypass vent valve communicates with outdoor air. The bypass vent valve is connected to the controller, and the controller is configured to control the bypass vent valve.

Abstract: A biflavone compound against an I-type herpes simplex virus, and a preparation method therefor and the use thereof. The bioflavone compound is a compound of formula I, or a crystal form thereof, or a salt thereof, or a stereoisomer thereof, or a solvate thereof, or a hydrate thereof, or a prodrug thereof. The biflavone compound has a good inhibitory effect on the I-type herpes simplex virus, has a significant effect on the replication and direct inactivation of the virus, and is dose dependent. The compound is also effective in preventing and/or treating viral keratitis caused by the I-type herpes simplex virus. The compound has good water solubility and low toxicity. It can be prepared into an external preparation for resisting the I-type herpes simplex virus, such as eye drops and eye ointment, and external ointments, creams, gel agents, film agents, film-coating agents, etc.

Abstract: This application provides a data storage method which is applied to a data storage device and includes: acquiring a first user identification and first user data of a first user; determining, from at least two preset distributed hosts in different areas, a first identification distributed host corresponding to the first user identification and a first data distributed host corresponding to the first user data; sending the first user identification to the first identification distributed host, so that the first identification distributed host stores the first user identification, and generates and stores a first identity identification corresponding to the first user identification; receiving the first identity identification; and sending the first identity identification and the first user data to the first data distributed host, so that the first data distributed host stores them in an associated manner.

Abstract: The present disclosure belongs to the technical field of lubricating material preparation, and specifically relates to a halloysite nanotube (HNT)-encapsulated ionic liquid (IL) microcapsule, a self-lubricating fiber textile composite, and a preparation method and use thereof. In the present disclosure, the preparation method includes the following steps: dispersing a HNT and an alkali metal salt of a saturated fatty acid in water, dispersing a resulting inner surface-modified HNT and an IL in an organic solvent, injecting the IL into the HNT in the mixed dispersion under vacuumizing to obtain an IL-filled HNT, and encapsulating a resulting IL-filled HNT at a tube end with an encapsulating material to obtain the HNT-encapsulated IL microcapsule.

Abstract: The present disclosure provides a page configuration method, a page configuration system, an electronic device and a readable storage medium. The page configuration method includes: generating, by the control device, a visualized configuration page; obtaining, by the control device, a display state of a control in the configuration page; generating, by the control device, a control parameter in accordance with the display state, the control parameter including a distance between the display position of the control and each boundary of the configuration page, and a ratio of the display size to a size of the configuration page; transmitting, by the control device, the control parameter to the terminal device; and determining, by the terminal device, a display state of the control in the terminal device in accordance with a display parameter of the terminal device and the control parameter.

Abstract: The present disclosure belongs to the technical field of lubricating material preparation, and specifically relates to a halloysite nanotube (HNT)-encapsulated ionic liquid (IL) microcapsule, a self-lubricating fiber textile composite, and a preparation method and use thereof. In the present disclosure, the preparation method includes the following steps: dispersing a HNT and an alkali metal salt of a saturated fatty acid in water, dispersing a resulting inner surface-modified HNT and an IL in an organic solvent, injecting the IL into the HNT in the mixed dispersion under vacuumizing to obtain an IL-filled HNT, and encapsulating a resulting IL-filled HNT at a tube end with an encapsulating material to obtain the HNT-encapsulated IL microcapsule.

Abstract: Provided in the present disclosure is a picture processing method, comprising: acquiring picture information of a picture, to be classified, of a first terminal, and according to the picture information, classifying said picture into at least one picture category of the first terminal; in response to satisfying a preset synchronization condition, acquiring a synchronous storage position of a second terminal, and determining the category of at least one picture, to be synchronized, of the first terminal; and for the category of each picture to be synchronized, determining a storage space, corresponding to the picture category, in the synchronous storage position, and transmitting the picture, of the first terminal, under the picture category to the storage space. Further provided in the present disclosure are an electronic device and a computer readable medium.

Abstract: Provided are a fusion protein and a construction method thereof. The fusion method consists of: a Haemophilus influenzae protein D and a Hin47 (Htra) protein. The fusion protein can serve as a protein vehicle for a Haemophilus influenzae polysaccharide-protein conjugate vaccine, thereby increasing immunogenicity of a polysaccharide antigen.

Abstract: The invention provides an immunogenic composition for preventing pneumococcal diseases, comprising PspA-MRX1, PspA-EF5668, PspA-EF3296 and PlyL460D, wherein the amount of each component is 10-100 ?g/ml; the immunogenic composition is prepared by adding to aluminum adjuvant the corresponding dosages of the four stock solutions PspA-mRX1, PspA-EF5668, PspA-EF3296 and PlyL460D, and mixing them homogeneously; the immunogenic composition can prevent infection and invasion by Streptococcus pneumonia, covering more than 95% of the strains in clinic. The immunogenic composition has a wide application in the prevention of pneumonia, and is suitable for large-scale production in industry for its simple preparation method, low production cost, and short production cycle.

Abstract: A method for enhancing immunogenicity of an epitope peptide of an HPV antigen, the method including: assembling a gene of an HPV antigen into a gene of HBc, exogenously expressing a resulting assembled gene to acquire a fusion protein, allowing the fusion protein to automatically assemble to form a virus-like particle including the HPV antigen on a surface of the virus-like particle, to obtain HBc-HPV virus-like particle. A virus-like particle capable of expressing the antigen peptide of HPV acquired by the method. The virus-like particle includes a HBc-L2 fusion protein. A genome for encoding the HBc-L2 fusion protein is represented by SEQ ID NO. 3. A method for preparing an HPV vaccine includes using the virus-like particle.

Abstract: The invention provides an immunogenic composition for preventing pneumococcal diseases, comprising PspA-MRXI, PspA-EF5668, PspA-EF3296 and PlyL460D, wherein the amount of each component is 10-100 ?g/ml; the immunogenic composition is prepared by adding to aluminum adjuvant the corresponding dosages of the four stock solutions PspA-mRXI, PspA-EF5668, PspA-EF3296 and PlyL460D, and mixing them homogeneously; the immunogenic composition can prevent infection and invasion by Streptococcus pneumonia, covering more than 95% of the strains in clinic. The immunogenic composition has a wide application in the prevention of pneumonia, and is suitable for large-scale production in industry for its simple preparation method, low production cost, and short production cycle.

Abstract: Provided are a fusion protein and a construction method thereof. The fusion method consists of: a Haemophilus influenzae protein D and a Hin47 (Htra) protein. The fusion protein can serve as a protein vehicle for a Haemophilus influenzae polysaccharide-protein conjugate vaccine, thereby increasing immunogenicity of a polysaccharide antigen.

Abstract: A method for enhancing immunogenicity of an epitope peptide of an HPV antigen, the method including: assembling a gene of an HPV antigen into a gene of HBc, exogenously expressing a resulting assembled gene to acquire a fusion protein, allowing the fusion protein to automatically assemble to form a virus-like particle including the HPV antigen on a surface of the virus-like particle, to obtain HBc-HPV virus-like particle. A virus-like particle capable of expressing the antigen peptide of HPV acquired by the method. The virus-like particle includes a HBc-L2 fusion protein. A genome for encoding the HBc-L2 fusion protein is represented by SEQ ID NO. 3. A method for preparing an HPV vaccine includes using the virus-like particle.

Abstract: In exemplary embodiments, the invention provides Pseudomonas fluorescens 2-79 strains having pyrrolnitrin biosynthetic genes for biocontrol of soilborne diseases.